 | Up a level |
Peyvandi, F; Scully, M; Kremer Hovinga, Johanna Anna; Knöbl, P; Cataland, S; De Beuf, K; Callewaert, F; De Winter, H; Zeldin, R K (2017). Caplacizumab reduces the frequency of major thromboembolic events, exacerbations, and death in patients with acquired thrombotic thrombocytopenic purpura. Journal of thrombosis and haemostasis, 15(7), pp. 1448-1452. Wiley-Blackwell 10.1111/jth.13716
Tripodi, A; Peyvandi, F; Chantarangkul, V; Palla, R; Afrasiabi, A; Canciani, M T; Chung, D W; Ferrari, S; Fujimura, Y; Karimi, M; Kokame, K; Kremer Hovinga, J A; Lämmle, B; de Meyer, S F; Plaimauer, B; Vanhoorelbeke, K; Varadi, K; Mannucci, P M (2008). Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). Journal of thrombosis and haemostasis, 6(9), pp. 1534-41. Oxford: Blackwell 10.1111/j.1538-7836.2008.03099.x
